103 completed, 48 active not recruiting, 32 recruiting, 31 terminated. 142 Phase 2, 103 Phase 1, 35 Phase 3, 4 Phase 4, 2 Not applicable.
Follow carfilzomib: new trials by email Literature Review of carfilzomib trials Research Report on carfilzomib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse Biospecimen Collection, Bone Marrow Biopsy, Carfilzomib - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 80 | 2027-05-22 | 2026-10-23 |
| Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration - Plasma Cell Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 74 | 2027-04-20 | 2026-10-07 |
| Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 162 | 2027-04-12 | 2026-10-16 |
| A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma Etentamig, Pomalidomide, Daratumumab - Relapsed or Refractory Multiple Myeloma | Phase 3 | Not yet recruiting | AbbVie | 520 | 2026-11-30 | 2026-07-27 |
| Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy Carfilzomib - Colorectal Neoplasms, Neoplasms | Phase 1 | Not yet recruiting | National Cancer Institute (NCI) | 20 | 2026-10-28 | 2026-10-23 |
| Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma InoPd, Investigator's choice of SAT - Multiple Myeloma Refractory, Multiple Myeloma in Relapse | Phase 3 | Recruiting | CellCentric Ltd. | 450 | 2026-08-01 | 2026-08-19 |
| A Single-center, Prospective, Single-arm Clinical Study Exploring the Treatment of Newly Diagnosed Multiple Myeloma Patients With t(11;14) Suitable for Transplantation Using the SonKRd Regimen Sotoclax, Carfilzomib, Lenalidomide - Newly Diagnosed Multiple Myeloma, T(11;14) | Phase 4 | Not yet recruiting | The First Affiliated Hospital of Soochow University | 20 | 2026-07-01 | 2026-07-17 |
| Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma Cevostamab, Pomalidomide, Dexamethasone - Multiple Myeloma | Phase 3 | Recruiting | Hoffmann-La Roche | 380 | 2026-06-23 | 2026-10-13 |
| KCD (Carfilzomib/Cyclophosphamide/Dexamethasone) Regimen for the Treatment of Newly Diagnosed POEMS Syndrome CARFILZOMIB, CYCLOPHOSPHAMIDE, DEXAMETHASONE - POEMS Syndrome | Phase 2 | Recruiting | Shanghai Changzheng Hospital | 20 | 2026-06-15 | 2026-06-17 |
| Treatment of Antibody-Mediated Rejection (ABMR) With CarBel Carfilzomib, Belatacept - Kidney Transplant Rejection | Phase 1 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 25 | 2026-05-27 | 2026-10-23 |
| Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma Selinexor, Carfilzomib, Isatuximab - Relapse Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Natalie Callander | 62 | 2026-05-21 | 2026-08-31 |
| A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM) Belantamab mafodotin, Dexamethasone, Pomalidomide - Multiple Myeloma | Phase 2 | Recruiting | GlaxoSmithKline | 200 | 2026-04-15 | 2026-08-25 |
| Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Withdrawn | Roswell Park Cancer Institute | 2026-04-01 | 2026-05-15 | |
| A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4) AZD0120, Daratumumab, Carfilzomib - Relapsed Refractory Multiple Myeloma | Phase 3 | Recruiting | AstraZeneca | 508 | 2026-02-23 | 2026-09-29 |
| A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM) Linvoseltamab, Carfilzomib, Daratumumab - Relapsed and/or Refractory Multiple Myeloma (RRMM) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 915 | 2026-01-02 | 2026-10-21 |
| A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations Etentamig, Lenalidomide, Dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | AbbVie | 602 | 2025-06-30 | 2026-10-19 |
| Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease Mezigdomide, Carfilzomib, Dexamethasone - Extramedullary Disease in Multiple Myeloma, Recurrent Multiple Myeloma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 28 | 2025-05-01 | 2026-08-18 |
| SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma Cxcr1/2 Inhibitor SX-682, Daratumumab and Recombinant Human Hyaluronidase, Carfilzomib - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Recruiting | Roswell Park Cancer Institute | 15 | 2025-04-10 | 2026-08-13 |
| Aponermin-Based Bridging Therapy Prior to CAR-T Infusion in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease anti-BCMA/GPRC5D bispecific CAR-T, Apornemin, Carfilzomib - Extramedullary Multiple Myeloma | Not applicable | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2025-04-09 | 2025-08-14 |
| A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma Isatuximab SC-OBDS, Montelukast, Dexamethasone - Plasma Cell Myeloma Refractory | Phase 2 | Recruiting | Sanofi | 64 | 2025-03-17 | 2026-02-23 |
Showing 20 of 245. Sign in to see all of them.
Multiple Myeloma (182) · Recurrence (33) · Neoplasms, Plasma Cell (16) · Lymphoma (11) · Neoplasms (8) · Lymphoma, Mantle-Cell (6) · Waldenstrom Macroglobulinemia (6) · Lymphoma, Large B-Cell, Diffuse (5) · Lymphoma, Non-Hodgkin (5) · Leukemia (4) · Smoldering Multiple Myeloma (4) · Carcinoma, Non-Small-Cell Lung (3) · Hematologic Neoplasms (3) · Hodgkin Disease (3) · Leukemia, Plasma Cell (3)
Amgen (26) · National Cancer Institute (NCI) (11) · M.D. Anderson Cancer Center (9) · University of Chicago (8) · Janssen Research & Development, LLC (6) · Mayo Clinic (6) · AbbVie (5) · Emory University (5) · Hackensack Meridian Health (5) · Memorial Sloan Kettering Cancer Center (5) · Sanofi (5) · Celgene (4) · European Myeloma Network B.V. (4) · Oncotherapeutics (4) · PETHEMA Foundation (4)
United States (180) · France (41) · Spain (41) · Canada (38) · Italy (36) · Germany (34) · United Kingdom (31) · Australia (28) · Greece (27) · Japan (25) · Czechia (23) · China (21) · South Korea (21) · Israel (20) · Belgium (19)
Andrzej Jakubowiak (3) · Brian GM Durie, MD (3) · Hun J. Lee, MD (3) · James R Berenson, MD (3) · Ravi Vij, M.D. (3) · Andrzej Jakubowiak, MD (2) · Benjamin Derman, MD (2)
PMID 33357481, PMID 35549810, PMID 26181891, PMID 26771810, PMID 31221778, PMID 32107329, PMID 36882409, PMID 21633906, PMID 22555973, PMID 22665938, PMID 22833546, PMID 22992303, PMID 23447001, PMID 24014245, PMID 24855212, PMID 24859363, PMID 24963043, PMID 25225420, PMID 25482145, PMID 25628469, PMID 25710456, PMID 25784682, PMID 26282654, PMID 26327694, PMID 26384354, PMID 26671818, PMID 26690712, PMID 27207788, PMID 27416912, PMID 28637662, PMID 29026685, PMID 29410301, PMID 29567784, PMID 30352784, PMID 30610196, PMID 30610657, PMID 30733270, PMID 30952640, PMID 31053600, PMID 31090915, PMID 31113777, PMID 31124580, PMID 31388932, PMID 31439537, PMID 31619706, PMID 31833394, PMID 32078124, PMID 32299820, PMID 32632956, PMID 32735641
2023 (11), 2016 (4), 2017 (4), 2019 (4), P30CA015083 (3), P30CA015704 (3), U10CA180820 (3), 2014 (2), 2018 (2), 2025 (2), P30CA016672 (2), P30CA138292 (2), P30CA014599 (1), P30CA016058 (1), P30CA033572 (1)